Pharma Foods International Co., Ltd. (JP:2929)
:2929
2929 Stock Chart & Stats
¥679.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥679.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥560.00 - ¥1,064.00
Previous CloseN/A
Volume159.60K
Average Volume (3M)110.46K
Market Cap
¥20.28B
Enterprise Value¥27.48B
Total Cash (Recent Filing)¥7.69B
Total Debt (Recent Filing)¥14.85B
Price to Earnings (P/E)72.7
Beta0.75
Next Earnings
Jun 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.65%
Share Statistics
EPS (TTM)2.43
Shares Outstanding29,079,000
10 Day Avg. Volume122,950
30 Day Avg. Volume110,460
Financial Highlights & Ratios
PEG Ratio-0.78
Price to Book (P/B)2.21
Price to Sales (P/S)0.39
P/FCF Ratio-12.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent revenue growth (+5.6% latest year) indicates durable demand for the company’s supplements and functional foods across channels. Steady top-line expansion supports scale economics, helps absorb fixed costs, and provides a platform for reinvestment in product development and distribution over the next 2–6 months.
High Gross MarginAn 80%+ gross margin signals strong product-level profitability and pricing power in formulations and branded supplements. High gross margins provide a structural buffer against raw material inflation and enable allocation of funds to marketing, R&D, or channel expansion without immediately eroding core profitability.
Reduced LeverageThe material reduction in debt-to-equity (2.38 → 1.09) meaningfully improves financial flexibility and lowers interest burden. Better leverage strengthens the balance sheet, making the company less vulnerable to funding shocks and better positioned to support operations, M&A, or working-capital needs over the medium term.
Bears Say
Net Margin CollapseA plunge in net margin from 5.16% to 0.56% is a structural red flag: it implies rising operating costs, weaker pricing power, or one-off losses that are eroding the company’s ability to convert sales into profits. Sustained low net margins will limit retained earnings and constrain strategic investments.
Negative Cash FlowNegative operating and free cash flow despite reported revenue growth indicates weak cash conversion and working capital stress. Persistent cash outflows erode liquidity, force reliance on external financing, and jeopardize dividend capacity or funding for product and channel expansion in the coming quarters.
Falling ROE & MarginsDeclining ROE and compressed EBIT/EBITDA margins point to weakening underlying profitability and capital efficiency. This trend reduces shareholder value creation, limits reinvestment capacity, and heightens sensitivity to competitive pressure or cost shocks over a medium-term horizon.
Pharma Foods International Co., Ltd. News
2929 FAQ
What was Pharma Foods International Co., Ltd.’s price range in the past 12 months?
Pharma Foods International Co., Ltd. lowest stock price was ¥560.00 and its highest was ¥1064.00 in the past 12 months.
What is Pharma Foods International Co., Ltd.’s market cap?
Pharma Foods International Co., Ltd.’s market cap is ¥20.28B.
When is Pharma Foods International Co., Ltd.’s upcoming earnings report date?
Pharma Foods International Co., Ltd.’s upcoming earnings report date is Jun 10, 2026 which is in 75 days.
How were Pharma Foods International Co., Ltd.’s earnings last quarter?
Pharma Foods International Co., Ltd. released its earnings results on Mar 13, 2026. The company reported ¥2.43 earnings per share for the quarter, beating the consensus estimate of N/A by ¥2.43.
Is Pharma Foods International Co., Ltd. overvalued?
According to Wall Street analysts Pharma Foods International Co., Ltd.’s price is currently Overvalued.
Does Pharma Foods International Co., Ltd. pay dividends?
Pharma Foods International Co., Ltd. pays a Semiannually dividend of ¥12.5 which represents an annual dividend yield of 3.65%. See more information on Pharma Foods International Co., Ltd. dividends here
What is Pharma Foods International Co., Ltd.’s EPS estimate?
Pharma Foods International Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharma Foods International Co., Ltd. have?
Pharma Foods International Co., Ltd. has 29,079,000 shares outstanding.
What happened to Pharma Foods International Co., Ltd.’s price movement after its last earnings report?
Pharma Foods International Co., Ltd. reported an EPS of ¥2.43 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 7.093%.
Which hedge fund is a major shareholder of Pharma Foods International Co., Ltd.?
Currently, no hedge funds are holding shares in JP:2929
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharma Foods International Co., Ltd.
Pharma Foods International Co., Ltd. engages in the development and sale of functional food ingredients in Japan. Its products include Pharma-GABA, Bonepep, Ovopron (egg yolk globulin), Delicious Catechin, RunPep, and enriched Folic Acid Egg, as well as iHA, a substance that stimulates secretion of hyaluronic acid. Pharma Foods International Co., Ltd. has licensing agreement with Mitsubishi Tanabe Pharma Corporation for a new therapeutic antibody to treat autoimmune diseases. Pharma Foods International Co., Ltd. was founded in 1997 and is based in Kyoto, Japan.
Technical Analysis
Hisamitsu Pharmaceutical Co
―
Tsumura & Co
―
Wakamoto Pharmaceutical Co., Ltd.
―
Morishita Jintan Co., Ltd.
―
Nippon Chemiphar Co., Ltd.
―
Options Prices
Currently, No data available
---